Demonstrated

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Significant Efficacy in Sufferers with HER2-Expressing, Recurrent Endometrial Most cancers
Press Releases

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Significant Efficacy in Sufferers with HER2-Expressing, Recurrent Endometrial Most cancers